Skip to main content

Last Updated on February 16, 2024

In recent years, digital communication has become an increasingly important tool for pharmaceutical companies to engage with healthcare professionals (HCPs). Initial focus is on collecting e-consent/e-permissions/opt-ins to start the digital customer journey. However, the preferences of doctors for digital communication can vary widely and understanding these preferences is essential for pharma companies to successfully engage with HCPs.

Here are a few reasons why it’s so important for pharmaceutical companies to capture preferences of doctors for digital communication:


One of the most significant advantages of digital communication is the ability to tailor messages to individual doctors’ preferences. By capturing and understanding doctors’ preferred channels, timing and content, pharmaceutical companies can provide personalized experiences that resonate with individual HCPs. This can increase engagement and build stronger relationships between pharma companies and doctors.

Efficient communication.

Digital communication channels can be more efficient than traditional methods such as face-to-face meetings or phone calls, although the mix of channels will certainly contribute. Understanding doctors’ preferences for digital channels such as email or social media can help pharma companies to streamline their communications and reduce the time and resources required to engage with HCPs.

Meeting HCPs where they are.

As digital communication becomes more ubiquitous, doctors are increasingly using digital channels to access information and communicate with each other. By capturing HCPs’ preferences for digital communication, pharma companies can meet doctors where they are and provide information in a way that is convenient and accessible to them.


Regulatory compliance is a critical concern for pharmaceutical companies and digital communication introduces new challenges in this area. Capturing HCPs’ preferences for digital communication can help pharma companies to ensure that they are communicating with doctors in a compliant manner, while still providing engaging and effective messaging.

Overall, capturing doctors’ preferences for digital communication is essential for pharmaceutical companies to effectively engage with HCPs in a way that is personalized, efficient and compliant. By doing so, pharma companies can build stronger relationships with doctors, increase engagement, and ultimately improve patient outcomes.

What can OptInsight do for you?

We offer solutions and services for pharma & life sciences companies with focus on increasing your reach to healthcare professionals (HCPs).

The OptInsight consent and preference management solution allows

pharmaceutical companies to manage the collection, storage and use of personal data in a compliant and secure manner. It provides a centralized platform for managing e-consent records (opt-ins AND opt-outs) and preferences, including the mandatory audit trail. It functions as a single source of truth, preventing scattered personal and consent data throughout your company. It also shows the latest consent status and preferences, which allows you to engage with HCPs based on the right data.

With our partner ecosystem, we can also support you on collecting opt-ins (up to 50%) and preferences (increase of up to 50% of HCP preferences), adding touch points to your customer journey with high end phone calls, improving the quality of data collected, creating social media campaigns, construction of websites and building HCP portals. Our very experienced pharma experts can support you at building the right governance structure for your company and at developing and implementing your omnichannel engagement strategy. Are you interested? Have a look at or contact me at

To stay updated, please follow us at LinkedIn

Schedule a meeting with us.

Tip: involve your colleagues from other departments within your company.
In this way we can instantly answer questions and provide clarity from various points of view.


Marketing & Product Director

Leave a Reply